SavedAdd your journal

Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2007 / Cilt: 41 - Sayı: 4

Lokalize prostat kanserinde aktif izlem politikasının yarar ve zararları

Tuna KARATAĞ
Mesrur Selçuk SILAY
Cengiz MİROĞLU
Pages
14–27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

KARATAĞ, T., SILAY, M. S., MİROĞLU, C. (2007). Lokalize prostat kanserinde aktif izlem politikasının yarar ve zararları. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 41 - Sayı: 4, 14–27. https://ajindex.com/articles/363891

References (14)

  1. Smith PH: The case for no initial treatment of localized prostate cancer. Urol Clin North Am 1990, 17:827-834
  2. Beynon LL, Busuttil A, Newsam JE, Chisholm GD: Incidental carcinoma of the prostate: selection for deferred treatment. Br J Urol 1983, 55:733-736
  3. Lowe BA, Listrom MB: Management of stage A prostate cancer with a high probability of progression. J Urol 1988, 140:1345-1347
  4. Christensen MM, Aagaard J, Madsen PO: Reasons for delay of endocrine treatment in cancer of the prostate (until symptomatic metastases occur). Prog Clin Biol Res 1990, 359:7-14; discussion 15-24
  5. Klotz LH, Nam RK: Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis. Can J Urol 2006, 13 Suppl 1:48-55
  6. Carter HB, Walsh PC, Landis P, Epstein JI: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002, 167:1231-1234
  7. Sakr WA, Haas GP, Cassin BF, Pontes JE et al: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993, 150:379-385
  8. Jemal A, Siegel R, Ward E, Murray T, Xu J et al: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130
  9. Hankey BF, Feuer EJ, Clegg LX, Hayes RB et al: Cancer surveillance series: interpreting trends in prostate cancer- -part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999, 91:1017-1024
  10. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101
  11. Galper SL, Chen MH, Catalona WJ, Roehl KA et al: Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006, 175:907-912
  12. Draisma G, Boer R, Otto SJ, van der Cruijsen IW et al: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95:868-878
  13. Parker C, Murton D, Melia J, Moss S, Dearnaley D. A model of natural history of screen-detected prostate cancer and effect of radical treatment on overall survival. Br J Urol 2006: 1122-1123 14. Pound CR, Partin AW, Eisenberger MA, Chan DW et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597
  14. Vis AN, Schroder FH, van de